UNITED THERAPEUTICS Corp — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
United Therapeutics announced a $477.6M Accelerated Share Repurchase (ASR) agreement with Citibank on September 8, 2026, to repurchase remaining shares under its $2B authorization. The company will make an upfront payment of ~$477.6M on/around September 10, 2026, receiving ~75% of anticipated shares immediately at the September 8 closing price, with final settlement in Q4 2026 based on volume-weighted average price. Combined with prior ASR repurchases of $1.5B in March 2026 and $22.4M in open-market purchases in Q3 2026, this completes the $2B program, returning ~$4B to shareholders over 2.5 years; as of September 4, 2026, the company had ~42.9M shares outstanding.
Why this rating
Share repurchase is routine capital allocation (~4.3% of $11.2B market cap). No operational change, no strategic shift, no new growth driver disclosed.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.